7 results
Primary objectives:*To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces therisk of a composite of myocardial infarction, stroke, or cardiovascular death in subjects with…
Performance of MRK, NexGen and LCS
Total Knee Prosthesis based on AP Stability Measurement and PROMS
Primary objective:Is there a significant difference in Anterior/Posterior stability between MRK, LCS and NexGen total knee prosthesis 1 year post-op?Secondary objectives:Is there a relevant correlation between Anterior/Posterior stability and…
To assess the safety and the efficacy on the activity part of the Steatosis Activity Fibrosis (SAF) histological score (inflammation and ballooning) of a 24-week treatment with two doses of lanifibranor (800, 1200 mg/24h) in NASH adult patients.
To determine if the use of apixaban in patients with SCAF will reduce the incidence of stroke and systemic embolism compared to aspirin.
1. Primary Objective The primary objective of this study is to assess the effect of lanifibranor alone compared toplacebo and the effect of lanifibranor in combination with empagliflozin compared to placeboon HbA1c after a 24-week treatment duration…
The study aims to evaluate a modified Anti-Platelet Therapy, when associated with low-dose rapamycin DES Firehawk in Acute Myocardial Infarction Patients treated with complete revascularization strategy.. The modified antiplatelet therapy consists…
The main objective is to assess the safety and feasibility of the direct omission of aspirin after PPCI with the continuation of ticagrelor monotherapy in STEMI patients. The secondary objectives are to demonstrate the reduction of IMH and infarct…